Skip to main content

Parkinson Disease Topic Center

Take the Quiz!
Quiz
03/07/2025
Think you know the key clinical features required to diagnose Parkinson disease? Put your knowledge of MDS criteria to the test!
Think you know the key clinical features required to diagnose Parkinson disease? Put your knowledge of MDS criteria to the test!
Think you know the key clinical...
03/07/2025
Neurology
An illustration of a brain against a blue background, with a deep brain stimulation device connected via electrodes
News
02/25/2025
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States...
02/25/2025
Neurology
fda building sign
News
02/04/2025
The US Food and Drug Administration (FDA) approved a drug-device combination to treat movement-related symptoms in advanced Parkinson disease.
The US Food and Drug Administration (FDA) approved a drug-device combination to treat movement-related symptoms in advanced Parkinson disease.
The US Food and Drug...
02/04/2025
Neurology
a patient with parkinson disease steadies a tremoring hand and wrist
News
01/16/2025
The beta-blocker propranolol reduces Parkinson disease (PD) tremor in both stressful and resting conditions, according to results from a placebo-controlled crossover trial published in the Annals of Neurology.
The beta-blocker propranolol reduces Parkinson disease (PD) tremor in both stressful and resting conditions, according to results from a placebo-controlled crossover trial published in the Annals of Neurology.
The beta-blocker propranolol...
01/16/2025
Neurology
FDA approval stamp
News
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
10/09/2024
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational...
10/09/2024
Neurology
News
09/30/2024
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper...
09/30/2024
Neurology
Pop quiz written on a blackboard with white chalk
Quiz
09/24/2024
Test your knowledge of recent research with this quiz!
Test your knowledge of recent research with this quiz!
Test your knowledge of recent...
09/24/2024
Neurology
A woman holds her forehead in pain with a migraine
News
08/28/2024
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving...
08/28/2024
Neurology
An older woman sits alone
News
08/27/2024
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson...
08/27/2024
Neurology